How much funding has Aerska raised?

Aerska has raised $39.0M in total funding, most recently a Series A round.

Who are Aerska's investors?

Aerska's investors include EQT Life Sciences.

Where is Aerska headquartered?

Aerska is headquartered in Dublin, Ireland.

What industry is Aerska in?

Aerska operates in Biotech, Healthcare.

Aerska

RNA medicines to treat, delay, and prevent diseases of the brain

Dublin, Ireland · Founded 2025 · $39.0M raised

Biotech

Healthcare

Headquarters: Dublin
Employees: 11–50
Founded: 2025
Business Model: B2B

Website: aerska.com
Total Funding: $39.0M
Last Round: $39.0M Series AFeb 2026
Rounds: 1

About

Aerska is a Dublin-based biotechnology company developing next-generation RNA interference (RNAi) medicines to treat, delay, and prevent diseases of the brain. The company's platform combines systemic administration with proprietary brain delivery technology to shuttle RNAi payloads across the blood-brain barrier, enabling targeted gene silencing in the central nervous system. Founded in 2025 by Jack O'Meara, Stuart Milstein, and David Hardwicke — veterans of Ochre Bio, Alnylam, and AveXis — Aerska launched with $21 million in seed funding and followed with a $39 million Series A in early 2026 to advance its pipeline against neurological diseases including Alzheimer's.

Summary

Aerska is a Biotech company based in Dublin, Ireland, founded in 2025. It has raised $39.0M in total across 1 round, most recently a $39.0M Series A round in Feb 2026. Investors include EQT Life Sciences.